The U.S. Supreme Court’s Increasing Involvement In Patent Law | Corporate LiveWire

Following April 29 oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the closely watched Supreme Court case on whether a generic drug manufacturer can be held liable...

Key Takeaway: Genetically engineered cultured host cells containing recombinant nucleic acids useful for gene therapy are patent-eligible for being markedly different from anything occurring in nature. In REGENXBIO Inc. v....

In interviews with Law360 and Life Sciences Intellectual Property Review, Knobbe Martens partner Jeremiah Helm offered insights into the Supreme Court’s decision to hear a petition of the Federal Circuit’s...